|
1
|
Kim J, Harper A, McCormack V, Sung H,
Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I and
Fidler-Benaoudia MM: Global patterns and trends in breast cancer
incidence and mortality across 185 countries. Nat Med.
31:1154–1162. 2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shirman Y, Lubovsky S and Shai A: HER2-low
breast cancer: Current landscape and future prospects. Breast
Cancer (Dove Med Press). 15:605–616. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wolff AC, Somerfield MR, Dowsett M,
Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA and
Allison KH: Human epidermal growth factor receptor 2 testing in
breast cancer. Arch Pathol Lab Med. 147:993–1000. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tozbikian G, Bui MM, Hicks DG, Jaffer S,
Khoury T, Wen HY, Krishnamurthy S and Wei S: Best practices for
achieving consensus in HER2-low expression in breast cancer:
Current perspectives from practising pathologists. Histopathology.
85:489–502. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gustavson MD, Bourke-Martin B, Reilly D,
Cregger M, Williams C, Mayotte J, Zerkowski M, Tedeschi G, Pinard R
and Christiansen J: Standardization of HER2 immunohistochemistry in
breast cancer by automated quantitative analysis. Arch Pathol Lab
Med. 133:1413–1419. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Larson JS, Goodman LJ, Tan Y, Defazio-Eli
L, Paquet AC, Cook JW, Rivera A, Frankson K, Bose J, Chen L, et al:
Analytical Validation of a highly quantitative, sensitive,
accurate, and reproducible assay (HERmark) for the measurement of
HER2 Total Protein and HER2 Homodimers in FFPE breast cancer tumor
specimens. Patholog Res Int. 2010(814176)2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Baehner FL, Achacoso N, Maddala T, Shak S,
Quesenberry CP Jr, Goldstein LC, Gown AM and Habel LA: Human
epidermal growth factor receptor 2 assessment in a case-control
study: Comparison of fluorescence in situ hybridization and
quantitative reverse transcription polymerase chain reaction
performed by central laboratories. J Clin Oncol. 28:4300–4306.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zimmerman BS and Esteva FJ:
Next-generation HER2-targeted antibody-drug conjugates in breast
cancer. Cancers (Basel). 16(800)2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nicolò E, Boscolo Bielo L, Curigliano G
and Tarantino P: The HER2-low revolution in breast oncology: Steps
forward and emerging challenges. Ther Adv Med Oncol.
15(17588359231152842)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Modi S, Jacot W, Yamashita T, Sohn J,
Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al:
Trastuzumab deruxtecan in previously treated HER2-low advanced
breast cancer. N Engl J Med. 387:9–20. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Modi S, Park H, Murthy RK, Iwata H, Tamura
K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, et
al: Antitumor activity and safety of trastuzumab deruxtecan in
patients with HER2-low-expressing advanced breast cancer: Results
from a phase Ib study. J Clin Oncol. 38:1887–1896. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Prat A, Cheang MCU, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal a breast cancer. J Clin Oncol. 31:203–209. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cho SY, Park SY, Bae YK, Kim JY, Kim EK,
Kim WG, Kwon Y, Lee A, Lee HJ, Lee JS, et al: Standardized
Pathology report for breast cancer. J Breast Cancer. 24:1–21.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Orrantia-Borunda E, Anchondo-Nuñez P,
Acuña-Aguilar LE, Gómez-Valles FO and Ramírez-Valdespino CA:
Chapter 3. Subtypes of Breast. Cancer. In: Breast Cancer
(Internet). Mayrovitz HN (ed). Exon Publications, Brisbane, AU,
2022.
|
|
16
|
Turova P, Kushnarev V, Baranov O, Butusova
A, Menshikova S, Yong ST, Nadiryan A, Antysheva Z, Khorkova S,
Guryleva MV, et al: The breast cancer classifier refines molecular
breast cancer classification to delineate the HER2-low subtype. NPJ
Breast Cancer. 11(19)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yersal O and Barutca S: Biological
subtypes of breast cancer: Prognostic and therapeutic implications.
World J Clin Oncol. 5:412–424. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gao JJ and Swain SM: Luminal A breast
cancer and molecular assays: A review. Oncologist. 23:556–565.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lee JS, Tocheny CE and Shaw LM: The
insulin-like growth factor signaling pathway in breast cancer: An
elusive therapeutic target. Life (Basel). 12(1992)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marin A, Morales F and Walbaum B:
Fibroblast growth factor receptor signaling in estrogen
receptor-positive breast cancer: Mechanisms and role in endocrine
resistance. Front Oncol. 14(1406951)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Eliyatkın N, Yalçın E, Zengel B, Aktaş S
and Vardar E: Molecular classification of breast carcinoma: From
traditional, old-fashioned way to a new age, and a new way. J
Breast Health. 11:59–66. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Godoy-Ortiz A, Sanchez-Muñoz A, Chica
Parrado MR, Álvarez M, Ribelles N, Rueda Dominguez A and Alba E:
Deciphering HER2 breast cancer disease: Biological and clinical
implications. Front Oncol. 9(1124)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J
and Shi B: Breast cancer intrinsic subtype classification, clinical
use and future trends. Am J Cancer Res. 5:2929–2943.
2015.PubMed/NCBI
|
|
24
|
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL,
Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR,
et al: Basal-like and triple-negative breast cancers: A critical
review with an emphasis on the implications for pathologists and
oncologists. Mod Pathol. 24:157–167. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bertucci F, Finetti P and Birnbaum D:
Basal breast cancer: A complex and deadly molecular subtype. Curr
Mol Med. 12:96–110. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Herschkowitz JI, Zhao W, Zhang M, Usary J,
Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, et
al: Comparative oncogenomics identifies breast tumors enriched in
functional tumor-initiating cells. Proc Natl Acad Sci USA.
109:2778–2783. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Voutsadakis IA: Comparison of clinical
subtypes of breast cancer within the claudin-low molecular cluster
reveals distinct phenotypes. Cancers (Basel).
15(2689)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Parker JS, Mullins M, Cheang MCU, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Burstein MD, Tsimelzon A, Poage GM,
Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al: Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 21:1688–1698. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Callahan R and Hurvitz S: Human epidermal
growth factor receptor-2-positive breast cancer: Current management
of early, advanced, and recurrent disease. Curr Opin Obstet
Gynecol. 23:37–43. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dawson JP, Berger MB, Lin CC, Schlessinger
J, Lemmon MA and Ferguson KM: Epidermal growth factor receptor
dimerization and activation require ligand-induced conformational
changes in the dimer interface. Mol Cell Biol. 25:7734–7742.
2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rubin I and Yarden Y: The basic biology of
HER2. Ann Oncol. 12 (Suppl 1):S3–S8. 2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cheng X: A comprehensive review of HER2 in
cancer biology and therapeutics. Genes (Basel).
15(903)2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hsu JL and Hung MC: The role of HER2,
EGFR, and other receptor tyrosine kinases in breast cancer. Cancer
Metastasis Rev. 35:575–588. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Müller V, Bartsch R, Lin NU, Montemurro F,
Pegram MD and Tolaney SM: Epidemiology, clinical outcomes, and
unmet needs of patients with human epidermal growth factor receptor
2-positive breast cancer and brain metastases: A systematic
literature review. Cancer Treat Rev. 115(102527)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Nader-Marta G, Martins-Branco D and de
Azambuja E: How we treat patients with metastatic HER2-positive
breast cancer. ESMO Open. 7(100343)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Schettini F, Chic N, Brasó-Maristany F,
Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M,
Barnadas E, et al: Clinical, pathological, and PAM50 gene
expression features of HER2-low breast cancer. NPJ Breast Cancer.
7(1)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Agostinetto E, Rediti M, Fimereli D,
Debien V, Piccart M, Aftimos P, Sotiriou C and de Azambuja E:
HER2-low breast cancer: Molecular characteristics and prognosis.
Cancers (Basel). 13(2824)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang G, Ren C, Li C, Wang Y, Chen B, Wen
L, Jia M, Li K, Mok H, Cao L, et al: Distinct clinical and somatic
mutational features of breast tumors with high-, low-, or
non-expressing human epidermal growth factor receptor 2 status. BMC
Med. 20(142)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Marchiò C, Dell'Orto P, Annaratone L,
Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A,
Rangel N, Casorzo L, et al: The dilemma of HER2 double-equivocal
breast carcinomas: Genomic profiling and implications for
treatment. Am J Surg Pathol. 42:1190–1200. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Howlader N, Altekruse SF, Li CI, Chen VW,
Clarke CA, Ries LA and Cronin KA: US incidence of breast cancer
subtypes defined by joint hormone receptor and HER2 status. J Natl
Cancer Inst. 106(dju055)2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pegram M, Jackisch C and Johnston SRD:
Estrogen/HER2 receptor crosstalk in breast cancer: Combination
therapies to improve outcomes for patients with hormone
receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer.
9(45)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hurtado A, Holmes KA, Geistlinger TR,
Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S and
Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2
determines response to tamoxifen. Nature. 456:663–666.
2008.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Anzick SL, Kononen J, Walker RL, Azorsa
DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and
Meltzer PS: AIB1, a steroid receptor coactivator amplified in
breast and ovarian cancer. Science. 277:965–968. 1997.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Torres-Arzayus MI, Font de Mora J, Yuan J,
Vazquez F, Bronson R, Rue M, Sellers WR and Brown M: High tumor
incidence and activation of the PI3K/AKT pathway in transgenic mice
define AIB1 as an oncogene. Cancer Cell. 6:263–274. 2004.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Fereshteh MP, Tilli MT, Kim SE, Xu J,
O'Malley BW, Wellstein A, Furth PA and Riegel AT: The nuclear
receptor coactivator amplified in breast cancer-1 is required for
Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis
in mice. Cancer Res. 68:3697–3706. 2008.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Denkert C, Seither F, Schneeweiss A, Link
T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch
C, et al: Clinical and molecular characteristics of
HER2-low-positive breast cancer: Pooled analysis of individual
patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol. 22:1151–1161. 2021.PubMed/NCBI View Article : Google Scholar
|
